Esketamine: A New Hope for Treatment-Resistant Depression (FDA Advisory Committees, 2019)

Introduction:
The FDA reviewed a new treatment called esketamine, a nasal spray developed for people with treatment-resistant depression (TRD). TRD is a serious condition where traditional antidepressants fail to work. This medication offers new possibilities for those who haven’t found relief with other options.

Key Points for Patients:

  1. What is Esketamine?
    • Esketamine is a nasal spray designed for adults whose depression hasn’t improved after trying multiple medications.
    • It is fast-acting, with effects often felt within hours to days.
  2. FDA Advisory Meeting (2019):
    • Experts analyzed whether esketamine is effective and safe.
    • The committee focused on potential risks, such as side effects like dizziness or dissociation, and how these compare to its benefits.
    • The review highlighted esketamine’s ability to rapidly reduce symptoms of depression, especially in urgent cases.
  3. How It Works:
    • Esketamine targets a different brain system than traditional antidepressants, offering hope for people whose depression hasn’t improved with common treatments.
  4. Safety Measures:
    • The FDA recommended controlled use, requiring patients to take the medication in a clinical setting under supervision.

The VitalPoint for Patients:
Esketamine provides a new option for people who feel like they’ve tried everything for their depression. If you or someone you know is struggling with treatment-resistant depression, talk to a doctor about whether this medication might be an option.

Learn More:

Depression FDA Ketamine Patient Regulation
Scroll to Top